Repository logo
 

Loss of ARPC1B impairs cytotoxic T lymphocytes maintenance and cytolytic activity

Published version
Peer-reviewed

Type

Article

Change log

Authors

Randzavola, Lyra 
Strege, Katherina 
Juzans, Marie 
Asano, Yukako 

Abstract

CD8 cytotoxic T lymphocytes (CTL) rely on rapid reorganization of the branched F-actin network to drive the polarized secretion of lytic granules, initiating target cell death during the adaptive immune response. Branched F-actin is generated by the nucleation factor Arp2/3 complex. Patients with mutations in the ARPC1B subunit of Arp2/3 show combined immunodeficiency with symptoms of immune dysregulation including recurrent viral infections and reduced CD8 T cell count. Here we show that loss of ARPC1B led to loss of CTL cytotoxicity, with the defect arising at two different levels. First ARPC1B is required for lamellipodia formation, cell migration and actin reorganisation across the immune synapse. Second, we found that ARPC1B is indispensable for the maintenance of TCR, CD8 and GLUT1 membrane proteins at the plasma membrane of CTL, as recycling via the retromer and WASH complexes was impaired in the absence of ARPC1B. Loss of TCR, CD8 and GLUT1 gave rise to defects in T cell signalling and proliferation upon antigen stimulation of ARPC1B-deficient CTL, leading to a progressive loss of CD8 T cells. This triggered an activation-induced immunodeficiency of CTL activity in ARPC1B-deficient patients, which could explain the susceptibility to severe and prolonged viral infections.

Description

Keywords

Adaptive immunity, Cell Biology, Cytoskeleton, Immunology, T cells, Actin-Related Protein 2-3 Complex, Actins, CD8 Antigens, Cell Polarity, Cytotoxicity, Immunologic, Glucose Transporter Type 1, HEK293 Cells, Humans, Immunological Synapses, Lymphocyte Activation, Receptors, Antigen, T-Cell, alpha-beta, T-Lymphocytes, Cytotoxic

Journal Title

Journal of Clinical Investigation

Conference Name

Journal ISSN

0021-9738
1558-8238

Volume Title

129

Publisher

American Society for Clinical Investigation
Sponsorship
Wellcome Trust (100140/Z/12/Z)
Wellcome Trust (103930/Z/14/Z)
This work was funded by Wellcome Trust grants [10390] and [100140] to G.M.G.